Table 1 Proportions of subjects with MenC serum bactericidal antibody titres ≥8/≥128, MenC serum bactericidal antibody geometric mean titres with 95% confidence intervals, anti-MenC IgG geometric mean concentration with 95% confidence intervals, anti-PRP Hib IgG geometric mean concentration with 95% confidence intervals and proportions of subjects with anti-PRP Hib IgG ≥ 0.15/≥1.00 μg/mL before and following vaccination with Hib/MenC-TT
| Â | Baseline | Following vaccination |
|---|---|---|
rSBA GMT (95% CI) | 151.2 (52.2 – 437.9) | 454.3 (200.9 – 1027.3) |
N (%) with rSBA titres ≥8 | 23/29 (79%) | 28/29 (97%) |
N (%) with rSBA titres ≥128 | 19/29 (66%) | 24/29 (83%) |
MenC IgG GMC (95% CI) μg/mL | 4.3 (2.1 – 8.8) | 6.6 (3.3 – 13.1) |
N (%) with anti-PRP Hib IgG concentrations ≥ 0.15 μg/mL | 18/29 (62%) | 29/29 (100%) |
N (%) with anti-PRP Hib IgG concentrations ≥ 1.00 μg/mL | 9/29 (31%) | 28/29 (97%) |
Anti-PRP Hib IgG GMC (95% CI) μg/mL | 0.23 (0.09 – 0.60) | 50.69 (24.28 – 105.84) |